Co-existing inflammatory bowel disease and Barrett’s esophagus is associated with esophageal dysplasia: a propensity score-matched cohort

Abstract

Background and study aims Barrettʼs esophagus (BE) and inflammatory bowel disease (IBD) predispose to the development of dysplasia and cancer. It is unclear if the inflammatory cascade seen in IBD affects disease progression in BE. We aimed to determine if patients with BE who have co-existing IBD had a higher risk of dysplasia, nodular disease, or longer segments than BE patients without IBD.

Patients and methods This was a multicenter, retrospective propensity score-matched cohort study. We compared rates of dysplasia, nodular disease, and segment length in patients with BE and IBD (cases) to patients with BE who did not have IBD (controls). Controls were 1:1 propensity score matched with controls for age, sex, body mass index (BMI), smoking, and hiatal hernia.

Results A total of 132 patients were included in the IBD + BE group and 132 patients in the BE group. Patients with IBD + BE had higher rates of esophageal dysplasia compared to controls (15.9 % vs. 6.1 % [adjusted odds ratio [OR]: 2.9, 95 % CI: 1.2–6.9]) and more nodules (9.8 % vs. 3.0 % [adjusted OR: 3.5, 95 % CI: 1.1–11.0]). IBD + BE group was also associated with longer BE segments (43.9 % vs. 12.1 % [OR: 5.7, 95 % CI: 3.0–10.6]).

Conclusions Co-existing IBD may increase the risk of dysplasia and esophageal nodules in patients with BE. Our findings may have implications for BE surveillance intervals in IBD patients. Prospective studies are needed to confirm our findings.

Publication History

Received: 12 February 2021

Accepted: 27 May 2021

Article published online:
16 September 2021

• References

• 1 Hayeck TJ, Kong CY, Spechler SJ. et al. The prevalence of Barrettʼs esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus 2010; 23: 451-457
• 2 Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrettʼs esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 2015; 44: 203-231
• 3 Spechler SJ. Barrettʼs esophagus. Semin Gastrointest Dis 1996; 7: 51-60
• 4 Spechler SJ. Disputing dysplasia. Gastroenterology 2001; 120: 1864-1868
• 5 Kestens C, Leenders M, Offerhaus GJ. et al. Risk of neoplastic progression in Barrettʼs esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study. Endoscopy 2015; 47: 409-414
• 6 Orloff M, Peterson C, He X. et al. Germline mutations in msr1, ascc1, and cthrc1 in patients with barrett esophagus and esophageal adenocarcinoma. JAMA 2011; 306: 410-419
• 7 Zhang HY, Hormi-Carver K, Zhang X. et al. In benign Barrettʼs epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. Cancer Res 2009; 69: 9083-9089
• 8 Rohr M, Aljabban J, Rudeski-Rohr T. et al. Meta-analysis reveals the prognostic relevance of nuclear and membrane-associated bile acid receptors in gastric cancer. Clin Transl Gastroenterol 2021; 12: e00295
• 9 Sun D, Wang X, Gai Z. et al. Bile acids but not acidic acids induce Barrettʼs esophagus. Int J Clin Exp Pathol 2015; 8: 1384-1392
• 10 Snider EJ, Compres G, Freedberg DE. et al. Barrettʼs esophagus is associated with a distinct oral microbiome. Clin Transl Gastroenterol 2018; 9: 135
• 11 Okereke IC, Miller AL, Jupiter DC. et al. Microbiota detection patterns correlate with presence and severity of Barrettʼs esophagus. Front Cell Infect Microbiol 2021; 11: 555072
• 12 Phillips WA, Lord RV, Nancarrow DJ. et al. Barrettʼs esophagus. J Gastroenterol Hepatol 2011; 26: 639-648
• 13 Turner D, Griffiths AM. Esophageal, gastric, and duodenal manifestations of IBD and the role of upper endoscopy in IBD diagnosis. Curr Gastroenterol Rep 2007; 9: 475-478
• 14 Pimentel AM, Rocha R, Santana GO. Crohnʼs disease of esophagus, stomach and duodenum. World J Gastrointest Pharmacol Ther 2019; 10: 35-49
• 15 Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013; 310: 627-636